## Featured news

[**64x Bio Launches LV Apex Suite, Expanding Its CellMap-Driven VectorSelect Platform Into Lentiviral Vector Production**](https://64xbio.com/articles/64x-bio-launches-lv-apex-suite-expanding-its-cellmap-driven-vectorselect-platform-into-lentiviral-vector-production)  
64x Bio

6/25/2026

[**64x Bio Launches AAV Apex Suite to Power the Next Generation of Gene Therapy Manufacturing**](https://64xbio.com/articles/64x-bio-launches-aav-apex-suite-to-power-the-next-generation-of-gene-therapy-manufacturing)  
64x Bio

6/16/2025

[**64x Bio Lands $55 Million for Gene-Therapy Tech**](https://www.wsj.com/articles/64x-bio-lands-55-million-for-gene-therapy-tech-11642595402)  
The Wall Street Journal

1/19/2022

### Press Releases

[**How CGT Leaders Are Reducing Failures, Scaling Processes, And Overcoming Regulatory Friction**](https://www.bioprocessonline.com/doc/how-cgt-leaders-are-reducing-failures-scaling-processes-and-overcoming-regulatory-friction-0001)  
Bioprocess Online

6/30/2025

[**Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models**](https://insights.citeline.com/in-vivo/business-strategy/mapping-biopharmas-ai-strategy-from-custom-datasets-to-foundation-models-NJMIZHQUEFDVTGBPQPQNJ55F6I/)  
Citeline

6/23/2025

[**At BIO, Companies Launch New Products for AAV Manufacturing, AI Drug Discovery**](https://www.genengnews.com/topics/bioprocessing/at-bio-companies-launch-new-products-for-aav-manufacturing-ai-drug-discovery/)  
Genetic Engineering & Biotechnology News

6/20/2025

[**64x Bio Unveils AAV Apex Suite to Address Gene Therapy Manufacturing Bottlenecks**](https://www.synbiobeta.com/read/64x-bio-unveils-aav-apex-suite-to-address-gene-therapy-manufacturing-bottlenecks)  
SynBioBeta

6/16/2025

[**How Church and Langer Make the Impossible Possible**](https://www.genengnews.com/topics/drug-discovery/how-church-and-langer-make-the-impossible-possible/)  
Genetic Engineering & Biotechnology News

10/30/2023

[**Interactive snapshot: 30 promising biotech startups**](https://www.drugdiscoverytrends.com/snapshot-30-promising-biotech-startups/)  
Drug Discovery & Development

8/24/2023

[**30 biotech startups making waves**](https://www.drugdiscoverytrends.com/30-biotech-startups-making-waves/)  
Drug Discovery & Development

8/24/2023

[**Here are the Bay Area's next generation of life science researchers**](https://www.bizjournals.com/sanfrancisco/news/2023/03/02/researchers-life-sciences.html)  
San Francisco Business Times

3/2/2023

[**The Neo CEO**](https://www.lifescienceleader.com/doc/the-neo-ceo-0001)  
Life Science Leader

3/1/2023

[**Top Life Sciences Startups to Watch in 2023**](https://www.biospace.com/article/top-life-sciences-startups-to-watch-in-2023/)  
BioSpace

12/5/2022

[**Alexis Rovner of 64x Bio is building genome engineering technologies to help patients**](https://www.youtube.com/watch?v=T4GvmSSmNKg)  
Bloomberg

11/15/2022

[**Gene therapies must become miracles of medicine**](https://www.economist.com/briefing/2022/08/25/gene-therapies-must-become-miracles-of-medicine)  
The Economist

8/25/2022

[**The Bloomberg New Economy Catalyst List**](https://www.bloomberg.com/features/2022-new-economy-catalyst-list/)  
Bloomberg

8/3/2022

[**Lex Rovner Wants to Transform AAV Manufacturing**](https://www.asgct.org/publications/news/june-2022/lex-rovner-aav-manufacturing)  
ASGCT

6/2/2022

[**Gene therapy at the crossroads**](https://www.nature.com/articles/s41587-022-01346-7)  
Nature Biotechnology

5/9/2022

[**Ep. 100 - Four Disruptive Forces In Biotech**](https://www.biotech2050.com/episodes/ep-100-four-disruptive-forces-in-biotech-7cc6l)  
BioTech 2050 Podcast

4/27/2022

[**The 20(+1) under 40: Your guide to the next generation of biotech leaders**](https://endpts.com/the-201-under-40-your-guide-to-the-next-generation-of-biotech-leaders/)  
Endpoints News

4/19/2022

[**Chirps, chats and Clubhouses: First-time biotech founders turn to social media for advice, investors and recruitment**](https://endpts.com/chirps-chats-and-clubhouses-first-time-biotech-founders-turn-to-social-media-for-advice-investors-and-recruitment/)  
Endpoints News

4/4/2022

[**The Last Major Technical Hurdle for Personalized Medicine: Manufacturability**](https://www.medtechintelligence.com/column/the-last-major-technical-hurdle-for-personalized-medicine-manufacturability/)  
MedTech Intelligence

2/3/2022

[**64x Bio’s iterative solutions to vector manufacturing pain points**](https://www.biocentury.com/article/641851/64x-bio-s-iterative-solutions-to-vector-manufacturing-pain-points)  
BioCentury

1/21/2022

[**64x Bio gains funding to advance cell line engineering platform**](https://www.scienceboard.net/index.aspx?sec=ser&sub=def&pag=dis&ItemID=3795)  
The Science Advisory Board

1/21/2022

[**64x Bio nets $55m Series A**](https://www.venturecapitaljournal.com/64x-bio-nets-55m-series-a/)  
Venture Capital Journal

1/19/2022

[**64x Bio Raises $55M To Advance Gene Therapy Platform**](https://news.crunchbase.com/news/64x-bio-55m-gene-therapy-manufacturing/)  
Crunchbase News

1/19/2022

[**Here is the 10-slide deck a new biotech company addressing a critical gene-therapy bottleneck used to raise $55 million in just a few months**](https://www.businessinsider.com/pitch-deck-64x-bio-raises-55-million-for-cell-gene-therapy-tools-2022-1)  
Business Insider

1/19/2022

[**64x Bio Raises $55 Million Series A Financing to Advance Cell Line Engineering Platform for Gene Therapy Manufacturing**](https://www.biospace.com/64x-bio-raises-55-million-series-a-financing-to-advance-cell-line-engineering-platform-for-gene-therapy-manufacturing)  
BioSpace

1/19/2022

[**A George Church spinout fighting the viral vector bottleneck in cell and gene therapy lands $55M**](https://endpts.com/a-george-church-spinout-fighting-the-viral-vector-bottleneck-in-cell-and-gene-therapy-lands-55m/)  
Endpoints News

1/19/2022

[**Harvard offshoot 64x Bio nets $55M in series A funding to expand cell production tech**](https://www.fiercepharma.com/manufacturing/harvard-offshoot-64x-bio-nets-55m-series-a-funding-to-expand-cell-production-tech)  
Fierce Pharma

1/19/2022

[**64x Bio Raises $55 Million Series A Financing to Advance Cell Line Engineering Platform for Gene Therapy Manufacturing**](https://64xbio.com/articles/64x-bio-raises-55-million-series-a-financing-to-advance-cell-line-engineering-platform-for-gene-therapy-manufacturing)  
64x Bio

1/19/2022

[**The Top 100 Yale Alumni In Technology of 2021**](https://www.thekeyexecutives.com/2021/06/25/the-top-100-yale-alumni-in-technology-of-2021/)  
Key Executives

6/25/2021

[**Introducing the Wyss Lumineers Class of 2020**](https://wyss.harvard.edu/news/introducing-the-wyss-lumineers-class-of-2020/)  
Wyss Institute

2/24/2021

[**International Day of Women and Girls in Science**](https://longevity.technology/news/international-day-of-women-and-girls-in-science/)  
Longevity Technology

2/11/2021

[**Viral vector start-up aims to tackle gene therapy Longevity bottleneck**](https://longevity.technology/news/viral-vector-start-up-aims-to-tackle-gene-therapy-longevity-bottleneck/)  
Longevity Technology

12/3/2020

[**64x claims cell screening tech is breakthrough for global vector supplies**](https://www.bioprocessintl.com/therapeutic-class/64x-claims-cell-screening-tech-is-breakthrough-for-global-vector-supplies)  
Bioprocess International

11/25/2020

[**George Church backs a startup solution to the massive gene therapy manufacturing bottleneck**](https://endpoints.news/george-church-backs-a-startup-solution-to-the-massive-gene-therapy-manufacturing-bottleneck/)  
Endpoints News

11/20/2020

[**64x Bio Emerges from Stealth to Drive an Evolution in Cell and Gene Therapy Manufacturing**](https://64xbio.com/articles/64x-bio-emerges-from-stealth-to-drive-an-evolution-in-cell-and-gene-therapy-manufacturing)  
64x Bio

11/16/2020